ArticleThe breast journal2025

Clinical Outcomes of CDK4/6 Inhibitor Therapy in HR+/HER2- Metastatic Breast Cancer: A Multicenter Comparison of HER2-Low and HER2-Zero Subgroups.

Erkan Ozcan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.